Daniel Simon discusses the GuardantINFORM™ platform featuring an extensive clinical-genomic liquid biopsy dataset of advanced cancer patients. The platform is intended to help accelerate research and development of the next generation of cancer therapeutics by offering biopharma partners an in-silico platform that combines de-identified longitudinal clinical information and genomic data collected from the Guardant360® liquid biopsy test —over 100,000 tests to date.
Daniel Simon, Senior Vice President, BioPharma Business Development at Guardant Health. Daniel Simon is responsible for building Guardant’s partnerships with pharmaceutical and biotechnology companies using the Digital Sequencing technology platform. Daniel brings more than a decade of experience in the life sciences industry across business development, strategy, and operations. Previously, Daniel served in roles at MyoKardia, Onyx Pharmaceuticals, McKinsey & Company, and Genentech. He holds an MBA from the University of Pennsylvania’s Wharton School and an MA Hons. in Natural Sciences from the University of Cambridge.